Stockscreener 앱 받기
4.49
0.22%
0.010
시간 외 거래:
4.48
-0.010
-0.22%
전일 마감가:
$4.48
열려 있는:
$4.53
하루 거래량:
178.32K
Relative Volume:
0.82
시가총액:
$186.77M
수익:
$2.00M
순이익/손실:
$109.16M
주가수익비율:
1.738
EPS:
2.5835
순현금흐름:
$-9.11M
1주 성능:
-5.07%
1개월 성능:
-11.44%
6개월 성능:
+31.29%
1년 성능:
+78.62%
1일 변동 폭
$4.39
$4.565
1주일 범위
$4.39
$4.795
52주 변동 폭
$2.09
$5.47
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
명칭
Oramed Pharmaceuticals Inc
전화
646-844-1164
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.49 | 196.76M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-12 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 개시 | Canaccord Genuity | Buy |
| 2021-02-09 | 개시 | National Securities | Buy |
| 2020-12-03 | 개시 | Alliance Global Partners | Buy |
| 2020-03-11 | 개시 | Aegis Capital | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2017-12-11 | 재개 | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 재확인 | FBR Capital | Outperform |
| 2015-12-01 | 재확인 | H.C. Wainwright | Buy |
| 2015-11-19 | 개시 | FBR Capital | Outperform |
| 2015-04-13 | 재개 | MLV & Co | Buy |
| 2014-01-30 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 개시 | MLV & Co | Buy |
| 2013-12-03 | 개시 | Aegis Capital | Buy |
모두보기
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 October By Investing.com - Investing.com Canada
An officer proposes selling 20,000 Oramed (ORMP) shares under a preset trading plan. - Stock Titan
A trading plan underpins an officer's proposed $140K share sale at Oramed (ORMP). - Stock Titan
40% of Oramed (ORMP) CFO’s stock award vests at grant; the rest vests over 24 months. - Stock Titan
Six option grants were canceled in exchange for a fully vested stock award to Oramed (ORMP) CEO Nadav Kidron. - Stock Titan
Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu - Barchart.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to S&P Global BMI Index - marketscreener.com
Oramed Pharmaceuticals stock trades quietly as investors weigh recent trial progress - AD HOC NEWS
Oramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Detailed Stock Data - The Chronicle-Journal
Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting - Investing.com
Oramed Pharmaceuticals (ORMP) moves to three-year pay votes - Stock Titan
Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Slips to $4.76, Holding Above $4.52 SupportLate Stage Breakouts - siam.in
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn
Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de
Oramed Pharmaceuticals Inc. (ORMP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness - Yahoo Finance
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn
Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - The Manila Times
MSN Money - MSN
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan
ORMP Q4 2025 Earnings: EPS Beat Drives Stock Gain as Revenue Remains N/AReturn On Assets - vinanet.vn
Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - marketbeat.com
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView
Oramed: Q2 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView
Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Oramed Pharmaceuticals (ORMP) Holds Steady at $4.33 as Range-Bound Trading PersistsSpring Pattern - dars.gov.et
ORMP | Oramed Pharmaceuticals Inc. Executive Compensation - Quiver Quantitative
ORMP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals announces annual shareholder meeting - Bitget
ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026) | ORMP ARS - Stock Titan
ORMP Q4 2025 Earnings: Profitable Quarter on Non-Operating Income as Stock RisesEstimate Revision Count - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Cash Flow - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oramed Pharmaceuticals Inc 주식 (ORMP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hexter Joshua | COO & CBO |
Oct 01 '26 |
Sale |
4.51 |
30,000 |
135,330 |
1,328,130 |
0.05%
0.82%
자본화:
|
볼륨(24시간):